Gainers at Biotech: Alcobra (NASDAQ:ADHD), Aratana Therapeutics (NASDAQ:PETX), Northwest Biotherapeutics (NASDAQ:NWBO), Agenus Inc (NASDAQ:AGEN), AEterna Zentaris (NASDAQ:AEZS)

Research analysts at WBB Securities initiated coverage on shares of Alcobra Ltd (NASDAQ:ADHD) in a report released on Thursday, 26 June 2014. The firm set a “hold” rating and a $18.00 price target on the stock. WBB Securities’ target price points to a potential upside of 5.76% from the company’s current price. Alcobra Ltd (NASDAQ:ADHD) stock performance was 5.85% in last session and finished the day at $18.99. Traded volume was 387,490.00million shares in the last session and the average volume of the stock remained 91.32K shares.

Aratana Therapeutics, Inc. (NASDAQ:PETX) announced that it has filed for a product license from the United States Department of Agriculture (USDA) for AT-014, a her2/neu-directed cancer immunotherapy licensed exclusively from Advaxis, Inc. (ADXS: Quote) for the treatment of canine osteosarcoma and other cancers. Aratana Therapeutics Inc (NASDAQ:PETX) rose 6.02 percent to $17.26 Wednesday on volume of 215,094.00million shares. The intra-day range of the stock was $16.25 to $17.32. Aratana Therapeutics Inc (NASDAQ:PETX) has a market capitalization of $508.27million.

The rating of Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) moves up this week, rising from a C to a B. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. Northwest Biotherapeutics, Inc (NASDAQ:NWBO)’s stock on July 02, 2014 reported a increase of 5.80% to the closing price of $7.30. Its fifty two weeks range is $3.10 -$10.64. The total market capitalization recorded $417.53million. The overall volume in the last trading session was 1.26million shares. In its share capital, NWBO has 57.19million outstanding shares.

Agenus Inc. (NASDAQ:AGEN) announced encouraging final results from a phase II study (n=46) on Prophage autologous cancer vaccine. Shares of the company jumped over 10% following the announcement. On Wednesday, shares of Agenus Inc (NASDAQ:AGEN) advanced 7.04% to close the day at $3.80. Company return on investment (ROI) is -581.40% and its monthly performance is recorded as 21.02%.  Agenus Inc (NASDAQ:AGEN) quarterly revenue growth is 18.38%.

Global Markets Direct’s, ‘AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) – Product Pipeline Review – 2014’, provides an overview of the AEterna Zentaris Inc. ‘s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of AEterna Zentaris Inc. ‘s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) stock performance was 6.61% in last session and finished the day at $1.29. Traded volume was 4.51million shares in the last session and the average volume of the stock remained 445.11K shares. The beta of the stock remained 1.64. AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) insider ownership is 7.06%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone